Sign In
Buy FULC
$3.58
-0.140 (-3.76%)
At Close: Jul 31, 2026
Fulcrum Therapeutics, Inc. (FULC) Shares March Higher, Can It Continue?
01:42pm, Thursday, 14'th May 2020
As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics, Inc. (FULC).
Fulcrum Therapeutics, Inc. (FULC) Q1 2020 Earnings Call Transcript
01:31am, Thursday, 14'th May 2020
With me on today's call are Robert Gould, president and chief executive officer; Diego Cadavid, senior vice president of clinical development; Owen Wallace, chief scientific officer; and Bryan Stuart,
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
11:00am, Wednesday, 13'th May 2020
Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and r
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
12:00am, Wednesday, 13'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 12)
Acceleron Pharma Inc (NASDAQ...
Fulcrum Therapeutics to Present at the BofA Securities 2020 Health Care Conference
11:00am, Monday, 11'th May 2020
CAMBRIDGE, Mass., May 11, 2020 -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with.
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
12:00am, Sunday, 10'th May 2020
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
Fulcrum Therapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Wednesday, May 13, 2020 at 8:00 a.m. ET
11:00am, Thursday, 07'th May 2020
CAMBRIDGE, Mass., May 07, 2020 -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with.
Fulcrum Therapeutics (NASDAQ:FULC) Receives Consensus Recommendation of "Buy" from Brokerages
06:28am, Wednesday, 22'nd Apr 2020
Fulcrum Therapeutics (NASDAQ:FULC) has earned an average recommendation of “Buy” from the six research firms that are currently covering the company, Marketbeat reports. One analyst has rated the
Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease
11:00am, Monday, 13'th Apr 2020
Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it is on track for sub
COVID-19 actions - healthcare
11:44am, Thursday, 02'nd Apr 2020
FDA signs off on Emergency Use Authorization for Humanigen's (OTCQB:HGEN) lenzilumab for compassionate use for preventing and treating cytokine storm in severely ill COVID-19 patients.Investigator-ini
Fulcrum Therapeutics Provides Business Update on Impact of COVID-19
11:00am, Thursday, 02'nd Apr 2020
CAMBRIDGE, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defin
Fulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
06:20pm, Tuesday, 24'th Mar 2020
Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced complete results from
144 Biggest Movers From Friday
09:03am, Monday, 16'th Mar 2020
Gainers
Contura Energy, Inc. (NYSE: CTRA) shares surged 64.7% to close at $4.89 on Friday. Contura is expected to release Q4 results on March 18.
Exterran Corporation (NYSE: EXTN...
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
01:05pm, Thursday, 05'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences In
Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2019 Financial Results
12:00pm, Thursday, 05'th Mar 2020
CAMBRIDGE, Mass., March 05, 2020 -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with.
